XYLOCARD 100 MG / 5 ML
LIDOCAINE HYDROCHLORIDE : 100 MG / 5 ML · DIN 00001937 · ASPEN PHARMACARE CANADA INC.
Health Canada status: MARKETED
What is XYLOCARD?
XYLOCARD 100 MG / 5 ML contains LIDOCAINE HYDROCHLORIDE : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00001937, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XYLOCARD used for?
XYLOCARD (lidocaine hydrochloride) by intravenous administration is indicated for: • the treatment of ventricular tachycardia occurring during cardiac manipulation (such as surgery or catheterization) or during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. This drug requires administration by experienced health professionals, with emergency resuscitative equipment and drugs immediately available.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00001937 |
|---|---|
| Brand name | XYLOCARD |
| Generic / active ingredient | LIDOCAINE HYDROCHLORIDE : 100 MG / 5 ML |
| Manufacturer | ASPEN PHARMACARE CANADA INC. |
| Strength | 100 MG / 5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | C01BB01 LIDOCAINE |
| AHFS class | 24:04.04.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Oct-2018 |
| Original market date | 1974-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
10 ampoules with a leaflet
Is LIDOCAINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C01BB01 LIDOCAINE. 4 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | 4 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00828602 |
| LIDOCAINE HYDROCHLORIDE INJECTION | 100 MG / 5 ML | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | DIN 02522268 |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00436208 |
| 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 4 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00478288 |
| LIDOCAINE 0.2% IN 5% DEXTROSE INJ | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00478296 |
| LIDOCAINE HCL 0.2% AND DEXTROSE 5% INJ | 50 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 00828599 |
| LIDOCAINE HCL 0.8% AND 5% DEXTROSE INJ | 50 MG | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 00828610 |
| LIDOCAINE HCL AND DEXTROSE 5% INJ USP | 400 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | DIN 01935976 |
| LIDOCAINE HCL AND DEXTROSE 5% INJ USP | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | DIN 01935968 |
| LIDOCAINE HCL INJ 20MG/ML | 20 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00565032 |
Who else supplies LIDOCAINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LIDOCAINE appears in 8211 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.